Hepatitis C Vaccines, Antibodies, and T Cells

Naglaa H. Shoukry1,2*

1Centre de Recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, QC, Canada, 2Département de médecine, Faculté de médecine, Université de Montréal, Montréal, QC, Canada

The development of vaccines that protect against persistent hepatitis C virus (HCV) infection remain a public health priority. The broad use of highly effective direct-acting antivirals (DAAs) is unlikely to achieve HCV elimination without vaccines that can limit viral transmission. Two vaccines targeting either the antibody or the T cell response are currently in preclinical or clinical trials. Next-generation vaccines will likely involve a combination of these two strategies. This review summarizes the state of knowledge about the immune protective role of HCV-specific antibodies and T cells and the current vaccine strategies. In addition, it discusses the potential efficacy of vaccination in DAA-cured individuals. Finally, it summarizes the challenges to vaccine development and the collaborative efforts required to overcome them.

Keywords: hepatitis C, vaccines, antibodies, T cells, reinfection

INTRODUCTION

Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection can achieve complete cure in >95% of cases (1, 2) and have been suggested to have the potential to eliminate an infection that affects more than 71 million individuals worldwide (3). It was suggested that with such effective treatments, a vaccine against HCV may no longer be needed (4). However, this argument may be overly optimistic. HCV infection can remain asymptomatic for years during which many infections go undiagnosed. It is estimated that only 5% of HCV cases worldwide are diagnosed (5, 6). Many current and new HCV infections occur in developing countries and among marginalized populations like people who inject drugs (PWIDs), incarcerated individuals, and men who have sex with men (7). These individuals are mostly disengaged from medical care with limited access to HCV screening and treatment. In the meantime, they continue to infect others and contribute to the ongoing epidemic. Indeed, the current opioid epidemic in North America has been associated with increased incidence of HCV (8). Medical procedures remain the major cause of new HCV infections in developing countries with high prevalence of HCV posing another risk factor within the general population and travelers to these areas (9). Finally, DAA treatment does not protect against reinfection further underscoring the need for an effective vaccine (10).

The World Health Organization (WHO) has set elimination targets for 2030 to reduce the rate of new HCV infections by 90% (11). Despite numerous success stories for implementation of national hepatitis C strategies with increased screening, diagnosis, and treatment, notably in places like the Republic of Georgia and Egypt (12–15), this will not be enough to curb HCV transmission on the long-term. Successful vaccination strategies at the population level have been the only reliable method to limit transmission of different viral infections by providing herd immunity (16), especially among vulnerable populations and in low-resource settings. The ongoing effort to eliminate HCV should include two arms: screening and treatment, and enhanced prevention via vaccination and harm reduction measures.
The quest to develop a vaccine against HCV has been active, since the discovery of the virus in 1989 but it has been a challenging endeavor due to the high variability of the virus and the lack of small animal models for preclinical testing. Strategies have aimed at either producing broadly neutralizing antibodies (bNAb) that would neutralize the infectivity of the virus or generating potent virus-specific CD4 and CD8 T cells that can eliminate infected hepatocytes. Various adjuvants, vectors, and vaccination regimens have been tested over the years. At present, two vaccines have made it into human preclinical and clinical trials. The first is a recombinant form of the virus envelope glycoproteins gpE1 and gpE2 aimed at inducing neutralizing antibodies and CD4 helper T cells (17, 18). The second is a vector-based vaccine encoding nonstructural (NS) proteins of the virus (NS3-NS5) using chimpanzee adenovirus priming and modified vaccinia Ankara (MVA) boost. This vaccine regimen was shown to induce high frequencies of virus-specific polyfunctional CD4 and CD8 T cells in healthy volunteers (19) and is currently in phase 2 clinical trials in PWIDs (NCT01436357). Results of this clinical trial are pending and will inform the field about the most appropriate future direction to follow.

This article reviews what we know about the role of antibodies versus T cells in mediating protective immunity against HCV and the pros and cons of targeting each approach in vaccine development. It also discusses the current challenges to HCV vaccine research and suggested collaborative efforts to overcome them.

**CORRELATES OF IMMUNE PROTECTION DURING ACUTE HCV**

Approximately 25% of individuals acutely infected with HCV are able to eliminate the virus spontaneously while the rest develop persistent infection and chronic liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma (20). The successful development of a vaccine against HCV is essentially informed by correlates of protective immunity induced during acute resolving infection. Multiple studies in humans and chimpanzees have clearly demonstrated the kinetic association of spontaneous viral clearance with induction of a broad, sustained HCV-specific CD4 and CD8 T cells [reviewed in Ref. (21)]. These T cell responses were also polyfunctional, producing multiple cytokines and effector functions (22). As the infection is cleared, virus-specific T cells develop a memory T cell phenotype and upregulate cell surface expression of the IL-7 receptor CD127 (22–25). The majority of HCV-infected individuals do generate a relatively broad CD4 and CD8 T cell response early on after infection that may afford partial control of viremia. Nevertheless, the abrupt loss of CD4 helper T cell responses, compromises CD8 T cell functionality and facilitates emergence of viral escape mutations in targeted CD8 T cell epitopes (26–28). As CD4 T cell functions are lost, the frequency of virus-specific T cells is reduced and the response becomes limited in breadth and/or functionality [reviewed in Ref. (21)]. Altogether, these dysfunctions result in virus rebound and persistent viremia. As the virus persists, CD8 T cells recognizing intact epitopes (i.e., epitopes that have not mutated) become exhausted and express exhaustion markers like programmed death 1 (PD1), T-cell immunoglobulin and mucin domain-containing-3 (Tim-3), cytotoxic T-lymphocyte protein 4 (CTLA4), 2B4, CD160, KLRG1, T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and CD39 (21, 29). In addition, they upregulate expression of the transcription factor comesodermin (Eomes), and in some cases the T cell factor 1 (TCF1) while downregulating expression of the T-box transcription factor (T-bet) (30, 31).

T cell exhaustion leads to progressive loss of effector functions resulting in reduced polyfunctionality, cytotoxicity, and loss of proliferative capacity [reviewed in Ref. (21)]. As the infection persists, the frequencies of HCV-specific CD8 and CD4 T cells detectable in peripheral blood are dramatically reduced (32, 33). During chronic infection, HCV-specific CD8 T cells are more readily detectable in the liver albeit with an exhausted phenotype (34, 35). Interestingly, CD8 T cells targeting epitopes that have mutated remain functional and detectable in peripheral blood and acquire a CD127+ memory T cell phenotype, similar to memory T cells generated following spontaneous resolution (36).

Early studies of antibodies (Abs) against the HCV glycoproteins gpE1 and gpE2 have suggested that these responses are delayed during acute infection and are not associated with control of viremia (37). Similarly, the early use of viral pseudoparticles suggested that the development of neutralizing Abs (NAb) is also delayed (38, 39). Yet, changes within the hypervariable region 1 (HVR1) of the gpE2 protein were detected in individuals developing chronic infection and were temporally correlated with Ab seroconversion suggesting immune selection pressure (40, 41). Furthermore, preincubation of virus inoculum with immune serum or anti-HVR1 Abs resulted in reduced infectivity in chimpanzees (42, 43). Passive immunization prolonged the incubation period in infected chimpanzees (44) and provided sterilizing immunity (45) or reduced viral loads in mouse models of HCV infection (46). Studies using multiple viral pseudoparticles representative of the variability of the virus gpE1/gpE2 region demonstrated a correlation between the generation of NAb and spontaneous resolution (47, 48). The isolation of bNAb from chronically infected and spontaneously resolved individuals and the capacity of these antibodies to block infectivity in mouse models of HCV infection further underscored the important protective effect of the antibody response (49–51).

**EVIDENCE OF PROTECTIVE IMMUNITY AGAINST HCV UPON RE-EXPOSURE AND REINFECTION**

Spontaneous clearance of HCV infection in chimpanzees and humans generates long-lived memory T cells that can theoretically protect against reinfection (52, 53). Long-term follow-up of a cohort of German women who were accidentally infected with HCV via a contaminated blood product demonstrated that spontaneous resolution of acute HCV generated long-lived memory T cells that can be detected up to 20 years post resolution while antibody responses waned with time (52). This observation suggested that T cell responses may provide more durable protective immunity than antibodies. Data from cohorts of PWIDs have reported reduced rates of reinfection and/or chronicity among
individuals with prior immunity to HCV as compared to HCV naïve controls with the same risk exposure (54). Studies in humans and chimpanzees have demonstrated that subsequent HCV exposures in individuals with resolved infection result in lower viral loads and shorter viremia as compared to primary infection in the same individuals (53, 55–60). HCV rechallenge was associated with rapid anamnestic immune response and associated with a blunted secondary infection or faster viral clearance (53, 55–57, 59). Experimental depletion of CD8 T cells from chimpanzees who had resolved primary HCV infection followed by a homologous rechallenge resulted in prolonged infection that resolved only upon recovery of virus-specific CD8 T cells (53). In a complementary experiment where CD4 T cells were depleted, the animals were never able to clear HCV reinfection and accumulated escape mutations in epitopes targeted by the CD8 response leading to viral breakthrough and persistent infection (61). These two studies underscored the important protective role of both CD4 and CD8 memory T cells in preventing HCV persistence.

Protection against viral persistence upon reinfection in PWIDs was associated with an increase in the magnitude and breadth of HCV-specific T cell responses, and polyfunctional memory T cells that can produce more than one cytokine or effector function (57, 59). Analysis of the T cell repertoire demonstrated that CD8 T cells expanding upon reinfection were derived from the memory T cell repertoire with almost no contribution of de novo T cell responses. Furthermore, the T cell repertoire became more focused upon reinfection with selection of T cells of the highest functional avidity (62).

Protection from viral persistence upon reinfection was also associated with generation of cross-reactive NAbs (57). These findings re-emphasized the important role of NAbs in mediating protective immunity and as a key component of a successful vaccine against HCV.

Protective immunity upon re-exposure was not absolute as some chimpanzees and humans could still develop chronic infection despite having strong immune responses upon heterologous rechallenge or infection with variant viruses that are not recognized by the pre-existing memory T cells (59, 63). These observations underscore the importance of inducing broad memory immune responses that target multiple epitopes or variant viruses.

In conclusion, reinfection in humans and chimpanzees confirmed the importance of both T cell responses and antibodies in long-term protective immunity. Furthermore, they underscored the importance of inducing a broadly reactive T cell and antibody response to counteract the variability in the viral quasispecies in real-world exposures. The recent development of better tools to examine the humoral response against HCV like pseudoparticles that are representative of the diverse viral populations (48), isolation of broadly neutralizing antibodies (49, 50), resolution of the crystal structure of the virus E2 glycoprotein (64, 65), understanding the interactions between NAbs and gpE2 (66, 67), and development of gpE2 tetramers that allow direct visualization, characterization, and isolation of HCV-specific B cells (68) will have an important impact on our understanding of the protective role of NAbs against HCV and the design of better vaccines.

**STERILIZING IMMUNITY VS PREVENTION OF PERSISTENCE**

The ideal goal of most vaccines is to provide sterilizing immunity that will protect against any infection upon exposure to the pathogen. This can only be achieved by induction of strong NAb responses that would neutralize infectivity. This approach has been very effective when targeting conserved viral surface proteins as is the case in vaccines against hepatitis A, B, and yellow fever. In the context of HCV, sterilizing immunity was not observed in chimpanzee rechallenge or human reinfection studies. Vaccination strategies aiming at inducing high titer bNAbs may indeed achieve sterilizing immunity but this will take time. Hence, it is likely that the first-generation vaccines will focus on achieving milder or blunted infections with lower viral loads and shorter periods of viremia and enhanced rate of viral clearance thus preventing viral persistence and protecting against chronic liver disease.

**CURRENT HCV VACCINE STRATEGIES**

Two main vaccine strategies are currently moving forward with human trials targeting either the cellular or humoral immune response (Table 1). The first vaccine is aimed at priming HCV-specific CD4 and CD8 T cells, using an adenovirus-based vector approach and focusing on the virus NS (NS3-NS4A-NS4B-NS5A-NS5B) proteins. The first proof-of-concept for this vaccine was demonstrated in the chimpanzee model of HCV infection. Adenoviral vectors serotype 6 (Ad6) and 24 (Ad24) carrying genes coding for the HCV NS proteins (genotype 1b) were used

**TABLE 1 | Current hepatitis C virus vaccine development strategies.**

| Main Target | Stage | Immunogen | Vaccine regimen | Induced immune response | Potential improvements |
|-------------|-------|-----------|----------------|------------------------|-----------------------|
| T cells     | Phase 2 | NS3-NS5 | Chimpanzee adenovirus 3 priming + modified vaccinia Ankara boost | Polyfunctional CD4 and CD8 T cells | More potent vectors (e.g., CMV) |
|             |       |          |                | No antibodies (Abs)    | Invariant chain combination (enhanced Ag presentation) |
|             |       |          |                |                        | Combination with recombinant proteins |
|             |       |          |                |                        | Combination with immune check point blockade (for direct-acting antiviral-treated subjects) |
| Antibodies  | Phase 1 | gpE1/gpE2 | Recombinant gpE1/ gpE2 + adjuvant (MF59C.1) | Some CD4 T cells, Broadly neutralizing antibodies | Better adjuvants |
|             |       |          |                |                        | Better CD8 T cell response inducers |
|             |       |          |                |                        | Combination with nonstructural proteins |
as prime followed by a plasmid DNA boost. Chimpanzees were then challenged with a heterologous virus (H77 and genotype 1a). This regimen led to priming of cross-reactive HCV-specific CD8 T cells in blood and liver that expanded upon rechallenge and led to suppression of acute viremia and lower viral loads in 4/5 vaccinated chimpanzees as compared to unvaccinated controls where 2/5 chimpanzees developed chronic infection (69). Subsequent testing in healthy human volunteers using human Ad6 priming and chimpanzee adenovirus 3 (ChAd3) boost, primed broad, polyfunctional, and cross-reactive HCV-specific CD4 and CD8 T cells that were sustained for at least a year after boosting with the ChAd3 and exhibited the phenotypic and functional characteristics of long-lived central and effector memory T cells (70, 71). The next-generation of this vaccine involved a heterologous prime-boost vaccination strategy based on ChAd3 priming then boosting with an MVA vector. This latest regimen was tested in healthy human volunteers and demonstrated optimal priming and boosting with the generation of high frequencies of polyfunctional, broad HCV-specific memory CD4 and CD8 T cells (19). This regimen is currently in phase 2 clinical trials as a prophylactic vaccine in high-risk PWIDs (NCT01436357). Results from this trial will provide the first proof of efficacy of this vaccine in real-life exposure to HCV.

The second vaccine is based on recombinant HCV gpE1/gpE2. This vaccine was one of the earliest vaccines tested in chimpanzees. Recombinant genotype 1a gpE1/gpE2 vaccination demonstrated effective immunogenicity and protective immunity against homologous or heterologous HCV rechallenge and even sterilizing immunity in some animals (72, 73). Preclinical evaluation of gpE1/gpE2 adjuvanted with MF59C.1 (an oil-in-water emulsion) in human volunteers induced NAb responses as well as proliferative CD4 T cell responses against gpE1/gpE2 (17, 74). This NAb response was cross-reactive and targeted multiple epitopes (18, 75).

These two vaccines targeting either T cell responses or antibody responses have demonstrated considerable immunogenicity in healthy volunteers and chimpanzees but whether they will provide protection during real-life exposures remains to be determined. Pending results of ongoing clinical trials will inform the future strategies of vaccine development. Next-generation vaccines against HCV will likely combine both T cell and antibody-based approaches into one single vaccine. The use of other strategies that may enhance immunogenicity like cytomegalovirus-based vectors (76) or fusion of the encoded antigen to major histocompatibility complex class II-associated invariant chain (II) (77) that have been reported to enhance CD8 T cell responses can be considered. The development of novel adjuvants and/or strategies that would tailor the T cell and antibody repertoires including the optimal vaccine/boost regimens and schedules are currently active areas of investigation.

## VACCINATION IN HCV-CURED INDIVIDUALS

HCV reinfection following DAA-mediated viral clearance remains a problem among individuals with high-risk behaviors like PWIDs (10, 78). Hence, they are one of the main groups in need of effective vaccination strategies that will either provide sterilizing immunity or protection against viral persistence upon reinfection. DAA cure of chronic HCV can normalize the majority of innate immune responses following viral clearance (79). However, data from the few studies that examined reconstitution of HCV-specific T cell responses post DAA cure have suggested only partial restoration of virus-specific immunity. Rapid restoration of the in vitro proliferative capacity of HCV-specific CD8 T cells and a slight reduction in the ex vivo expression of PD1 on HCV-specific CD8 T cells were reported (80, 81). TCF1+CD127+PD1+ HCV-specific CD8 T cells expressing both exhaustion and memory markers were described in chronically infected subjects and maintained during and after treatment (82). However, these “memory-like” CD8 T cells were different as compared to conventional memory T cells as they expressed higher levels of Eomes and TCF1 and produced lower levels of IFN-γ and TNF-α upon antigenic stimulation (82). Effect of DAA treatment on restoration of HCV-specific CD4 T cells, the hallmark of protective immunity, is unknown. Whether such partial restoration of HCV-specific immunity will protect against reinfection has not been tested in humans but a preliminary study in one chimpanzee treated with DAA reported that an intrahepatic HCV-specific CD8 T cell response was maintained at 2 years following cure but was narrowly focused and failed to prevent persistence upon re-challenge (83).

Given that the HCV-specific immune response had already failed once and is likely to be incompletely restored in DAA-cured individuals, it is not clear if they will respond to vaccination and whether they will be able to generate de novo T cell and/or Ab responses that can mediate protective immunity. A combined DAA therapy and immunization strategy with genetic vaccines encoding the NS proteins in chimpanzees chronically infected with HCV primed multifunctional T cell responses against non-conserved MHC class I epitopes (84). However, this response failed to contain the infection with the emergence of DAA resistance mutations (84). Vaccination with the NS genes using the ChAd3 prime/MVA, that has demonstrated high immunogenicity in healthy volunteers, did not efficiently reconstitute HCV-specific T-cell immunity in HCV chronically infected patients (85). Vaccine-induced HCV-specific CD8 T cell responses were induced in 8/12 patients but CD4 T-cell responses were rarely induced. This was true even in patients with low viral loads suppressed with interferon/ribavirin therapy. Furthermore, the overall magnitude of HCV-specific T-cells was much lower than that observed in vaccinated healthy volunteers and the HCV-specific cells exhibited a partially functional phenotype. In vitro expansion studies demonstrated that these specificities were derived from pre-existing low-level memory T cell populations that could be expanded by vaccination. Nevertheless, new T cell responses were induced when there was a sequence mismatch between the autologous virus and the vaccine immunogen (85). These preliminary studies suggest that it may be possible to prime new immune responses in chronic and HCV-cured individuals but it is not yet clear if they will be enough to mediate protective immunity upon re-exposure. As suggested elsewhere, it is possible that the vaccination requirements or threshold of priming a protective immune response will be different in this population.
(86). Additional strategies that may enhance immunogenicity like the use of novel adjuvants, vectors, or combination with immune checkpoint inhibitors may be interesting avenues to follow. Inclusion of DAA-cured individuals in upcoming vaccine trials will be necessary to evaluate immunogenicity in that special population.

**CHALLENGES OF VACCINE DEVELOPMENT AGAINST HCV**

Several challenges remain before achieving a vaccine that can be administered to the general population. Overcoming them will require collaborative efforts from the HCV community. These challenges include:

**Virus Variability**

There are 7 HCV genotypes and 67 subtypes (87). Furthermore, the virus circulates as quasispecies. Vaccination strategies targeting cross-reactive antibodies and T cell responses as well as conserved epitopes are likely to lead to better results. Data so far, suggest that the two HCV vaccines currently in progress can produce such responses, but additional methods to enhance their immunogenicity and broaden the response are needed to provide better vaccine coverage. It is also important to explore additional antigen design approaches that may overcome variability of HCV through the use of consensus sequences, ancestral, or mosaic sequences.

**Immunological Challenges**

The heterogeneity in the viral populations is compounded by the diversity of the vaccine-targeted human population. Specifically, for T cell-based vaccines, it will be important to design antigens that can be presented by multiple MHC alleles. It will also be critical for vaccination regimens to overcome the intrinsic host factors associated with several of the HCV at-risk populations that may influence the immune response, including: ethnicity, age, liver disease stage, opioid usage, and HIV co-infection. Designing prime/boost strategies and vaccination schedules that would promote expansion of the ideal T cell response (eg., polyfunctional, rapid proliferation, etc.) as well as bNAbs should be considered. Furthermore, as discussed above, tailoring specific vaccination regimens that would broaden the immune response in HCV-cured individuals may be essential.

Despite the progress in our understanding of correlates of protective immunity against HCV, several basic questions remain and require additional research to decipher them. First, although we know a lot about what constitute a good immune response against HCV, we do not understand why only ~25% of infected individuals are able to generate such a response. Second, CD4 T cell dysfunction is definitely key to developing persistent viremia but mechanisms of failure/exhaustion of these CD4 T cells remain unknown. Similarly, the molecular mechanisms underlying CD8 T cell exhaustion and dysfunction remain poorly understood. Third, the function of B cells during acute and chronic HCV, the interaction between T and B cells and how this impacts development of bNAbs are understudied. Future research to answer these questions should inform the vaccine development efforts.

**Lack of Preclinical Small Animal Models**

Humans and chimpanzees are the only two species that are susceptible to HCV infection. The efficacy of the two vaccines currently in clinical trials was demonstrated first in challenge studies in chimpanzees. With the moratorium on chimpanzee research, use of this model is no longer feasible (88). Furthermore, most mouse models that recapitulate the HCV life cycle are generated on immune-deficient backgrounds thus rendering them of limited use for preclinical vaccine testing but helpful in validating the in vivo neutralization capacity of antibodies (89). Novel mouse models using a hepativirus isolated from the Norway rats of New York city and termed the Norway rat hepativirus (NrHV) or rodent hepativirus-nr-1 can recapitulate some but not all aspects of the immune response to a hepativirus like HCV (90, 91). Specifically, depletion of CD4 T cells is required to achieve persistent viremia in this model (90). Nevertheless, it can still provide important clues about the correlates of immune protection and can be very useful in preclinical testing of novel adjuvants and vectors as well as vaccination regimen. Interestingly, NrHV infection in its original host, the rat, mimics to a great extent HCV infection in humans including the propensity to persist (92). From that perspective, the rat model of NrHV infection may be the more appropriate model to study immunity and vaccination, although the availability of rat-specific immune reagents is limited. Additional research aimed at establishing a more straightforward immune competent small animal model is still needed.

**Cohorts for Clinical Trials**

One of the difficulties in clinical trials is recruitment of high risk study subjects. Given that the main risk group for HCV infection is PWIDs who also suffer from multiple social, psychological, and marginalization issues, working with this group is challenging (93). Collaborative efforts with organized cohorts around the world are ongoing (94) and should be maximized in preparation for expanding the current clinical trials or new ones. With the current availability of highly effective DAAs, it is tempting to propose clinical trials of vaccines in healthy volunteers followed by challenge and close monitoring where DAA treatment can be administered at the first sign of viral persistence. This is not a novel approach and has been used in trials for malaria vaccines (95). Evidently, the ethical implications are not trivial and will have to be considered carefully.

**Standardized Reagents, Reagent Repositories, and Immunological Methods to Assess Vaccine Efficacy**

The advancement of our knowledge of protective immunity requires the availability of standardized reagents for testing as well as immune monitoring protocols. Peptides and a number of other reagents are available through the Biodefense and Emerging Infections Research Resources Repository (BEI Resources). Efforts to establish a repository for HCV pseudoparticles were discussed at the 24th International Symposium on HCV and Related Virus. Additional efforts to standardize immune monitoring among different trials should be considered.
Funding
Hepatitis C virus research is far from over. As discussed elsewhere (96), the road to HCV elimination requires additional investment in basic research on HCV to understand the molecular mechanisms of immune control of the virus and to develop effective vaccines. In addition, large-scale clinical trials and infrastructure support for production of large-scale vaccine lots under GMP conditions are costly. Such funding will have to be secured from collaborative initiatives by governments and funding agencies across the world, the WHO, and academic-industrial partnerships.

CONCLUDING REMARKS
Tremendous progress in the development of vaccines against HCV has occurred in recent years. The next-generation of HCV vaccines will have to target both antibodies and T cells for effective protective immunity. Better understanding of correlates of protection from viral persistence in real-life exposure settings and in DAA-cured individuals will be necessary for the design of new clinical trials. Similarly, better understanding of the humoral immune response and factors that may enhance the generation of bNAbs are warranted. Development of novel adjuvants, vectors, and vaccine prime/boost regimens that broaden the specificity and enhance the immunogenicity of vaccines are needed. Collaborative efforts for the establishment of cohorts and conducting vaccine clinical trials are essential.

AUTHOR CONTRIBUTIONS
NHS reviewed the literature and wrote the manuscript.

REFERENCES
1. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol (2015) 62:S87–99. doi:10.1016/j.jhep.2015.02.006
2. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JR, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med (2017) 166:367–48. doi:10.7326/M16-2575
3. WHO. Global Hepatitis Report, 2017. Geneva, Switzerland: WHO (2017).
4. Rice CM, Saeed M. Hepatitis C: treatment triumphs. Nature (2014) 510:43–4. doi:10.1038/nature13304
5. Gravitz L. Introduction: a smouldering public-health crisis. Nature (2011) 474:52. doi:10.1038/47452a
6. Cox AL. MEDICINE. Global control of hepatitis C virus. Science (2015) 349:790–1. doi:10.1126/science.aad1302
7. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 19:850–8. doi:10.1038/nm.3184
8. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis (2014) 59:1411–9. doi:10.1093/cid/ciu463
9. Thurne M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Rev Gastroenterol Hepatol (2013) 11:28. doi:10.1038/rngastro.2013.179
10. Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat (2018) 25:220–7. doi:10.1111/jvh.12859
11. WHO. Combating Hepatitis B and C to Reach Elimination by 2030. Geneva, Switzerland: World Health Organization (2016).
12. Gvinjilia L, Nasrullah M, Sergeenko D, Tsirtsvadze T, Kamkamidze G, Butasvili M, et al. National progress toward hepatitis C elimination – Georgia, 2015–2016. Morb Mortal Wkly Rep (2016) 65:1132–5. doi:10.15585/mmwr.mm65s1a2
13. Nasrullah M, Sergeenko D, Gvinjilia L, Gamkrelidze A, Tsirtsvadze T, Butasvili M, et al. The role of screening and treatment in national progress toward hepatitis C elimination – Georgia, 2015–2016. Morb Mortal Wkly Rep (2017) 66:773–6. doi:10.15585/mmwr.mm6629a2
14. Kouyoumnian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep (2018) 8:1661. doi:10.1038/s41598-017-17936-4
15. World-Bank. Eliminating Hepatitis C from Egypt: 2017 Update on Current Trends and Policy Recommendations – Policy Brief (English). Egypt’s Viral Hepatitis Program. Washington, D.C.: World Bank Group (2018).
16. Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis (2011) 52:911–6. doi:10.1093/cid/cir067
17. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rossa D, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 28:6367–73. doi:10.1016/j.vaccine.2010.06.084
18. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gE1/gE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 8:e59776. doi:10.1371/journal.pone.0059776
19. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoaviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med (2014) 6:261ra153. doi:10.1126/scitranslmed.3009185
20. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology (2002) 36:S21–9. doi:10.1002/hep.10430
21. Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 5:274. doi:10.3389/fimmu.2014.00274
22. Badr G, Bedard N, Abdel-Hakeem MS, Trautmann L, Willems B, Villeneuve JP, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol (2008) 82:10017–31. doi:10.1128/JVI.01083-08
23. Golden-Mason L, Burton JR Jr, Castelblanco N, Klarquist J, Benlloch S, Wang C, et al. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 44:1098–109. doi:10.1002/hep.21365
24. Bengsch B, Spangenberg HC, Kersting N, Neumann-Haefelin C, Panther E, Von Weizsacker F, et al. Broadly directed virus-specific CD4+ T cell responses are heterogeneous in hepatitis C virus infection associated with viral persistence. Front Immunol (2014) 5:274. doi:10.3389/fimmu.2014.00274
25. Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, De Re V, et al. The frequency of CD127+ HCV-specific T cells but not the expression of exhaustion markers predict the outcome of acute hepatitis C virus infection. J Virol (2013) 87(8):4772–7. doi:10.1128/JVI.01354-06
26. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med (2005) 201:1709–14. doi:10.1084/jem.20050808
27. Sermon N, Kleinerman P. CD4+ T cell responses in hepatitis C virus infection. World J Gastroenterol (2007) 13:4831–8. doi:10.3748/wjg.v13.i36.4831
28. Schulze zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprovicz V, Nolan BE, Streuck H, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human
blood with viral persistence. *J Exp Med* (2012) 209:61–75. doi:10.1084/jem.20100388

29. Gruber J, Hodec J, Wolski D, Adland E, Yates K, Pauken KE, et al. CD39 expression identifies terminally exhausted CD8+ T cells. *PloS Pathog* (2015) 11:e1005177. doi:10.1371/journal.ppat.1005177

30. Paley MA, Krov DC, Odorizzi PM, Johnnids JB, Dolfi DV, Barnett BE, et al. Progenitor and terminal subsets of CD8+ T-cells cooperate to contain chronic viral infection. *Science* (2012) 338:1220–5. doi:10.1126/science.1229620

31. Utschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. *Immunity* (2016) 45:415–27. doi:10.1016/j.immuni.2016.07.021

32. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. *J Exp Med* (2000) 191:1499–512. doi:10.1084/jem.191.9.1499

33. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. *J Exp Med* (2001) 194:1395–406. doi:10.1084/jem.194.10.1395

34. He XS, Rehermann B, Lopez-Labrador FX, Boisvert J, Cheung R, Mumm J, et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. *Proc Natl Acad Sci U S A* (1999) 96:5692–7. doi:10.1073/pnas.96.10.5692

35. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, et al. Malaria C3Bf: an inhibitory receptor on cytotoxic T cells. *Science* (2001) 294:1099–1102. doi:10.1126/science.294.5548.1099

36. Kasprowicz V, Kang YH, Lucas M, Schulze Zur Wiesch J, Kuntzen T, Fleming V, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. *J Exp Med* (2000) 191:1499–512. doi:10.1084/jem.191.9.1499

37. Farci P, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. *Proc Natl Acad Sci U S A* (2007) 104:6025–30. doi:10.1073/pnas.0607026104

38. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of Hepatitis C infection is associated with early appearance of broad neutralizing antibody responses. *Hepatology* (2014) 59(6):2140–51. doi:10.1002/hep.27013

39. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamatika Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. *Nat Med* (2008) 14:25–7. doi:10.1038/nm1698

40. Giang E, Dorner M, Prentoe JC, Drexu M, Evans MJ, Bukh J, et al. Human broad neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. *Proc Natl Acad Sci U S A* (2012) 109:6205–10. doi:10.1073/pnas.114927109

41. Bailey JR, Fylyak AI, Cohen VL, L H, Waslewski LN, Snider AE, et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. *JCI Insight* (2017) 2(9):e92872. doi:10.1172/jci.insight.92872

42. Takaki A, Wiese M, Maertens G, Depla E, Peifer D, Lieberau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. *Nat Med* (2000) 6:578–82. doi:10.1038/75063

43. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD122 expression. *J Virol* (2007) 81:2545–53. doi:10.1128/JVI.02021-06

44. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis* (2001) 33:2425–31. doi:10.1086/323716

45. Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. *Proc Natl Acad Sci U S A* (2004) 101:10149–54. doi:10.1073/pnas.0403519101

46. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. *Hepatology* (2002) 36:578–82. doi:10.1038/75063

47. Basset SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. *Hepatology* (2013) 47:1339–47. doi:10.1001/jem.2003.24371

48. Major ME, Mihalkí K, Puig M, Rehermann B, Nascimbeni M, Rice CM, et al. Selectively infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. *J Virol* (2002) 76:6586–95. doi:10.1128/JVI.76.13.6586-6595.2002

49. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. *Gastroenterology* (2010) 138:315–24. doi:10.1016/j.gastro.2009.09.017

50. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. *Lancet Infect Dis* (2012) 12:408–14. doi:10.1016/S1473-3099(12)70010-5

51. Abdel-Hakeem MS, Bedard N, Murphy D, Bruneau J, Shoukry NH. Signatures of protective memory immune responses during hepatitis C virus reinfection. *Gastroenterology* (2014) 147:870–81.e8. doi:10.1053/j.gastro.2014.07.005

52. Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, et al. Hepatitis C virus reinfection and spontaneous clearance of reinfection—the InC3 Study. *J Infect Dis* (2015) 212:1407–19. doi:10.1093/infdis/jiv220

53. Grebely J, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Gryzjew J, et al. HCV persistence and immune evasion in the absence of memory T cell help. *Science* (2003) 302:659–62. doi:10.1126 science.1088774

54. Abdel-Hakeem MS, Boisvert M, Bruneau J, Soudheyn H, Shoukry NH, et al. Selective expansion of high functional avidity memory CD8 T cell clonotypes during hepatitis C virus reinfection and clearance. *PloS Pathog* (2017) 13:e1006191. doi:10.1371/journal.ppat.1006191

55. Bukh J, Thimme R, Meunier JC, Faulk K, Spangenberg HC, Chang KM, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. *J Virol* (2008) 82:8183–95. doi:10.1128/jvi.00142-08

56. Krajewski T, Eikenes T, Kipervasser P, Kiperschmidt C, Hube H, Greve J, et al. Hepatitis C virus E2 envelope glycoprotein core structure. *Science* (2013) 342:1090–4. doi:10.1126/science.1243876

57. Khan AG, Whidy J, Miller MT, Scarborough H, Zatorski AV, Cogan A, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. *Nature* (2014) 509:381–4. doi:10.1038/nature13117

58. Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, et al. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus
neuralization by AP33, a broadly neutralizing antibody. *J Virol* (2012) 86:12923–32. doi:10.1128/JVI.02052-12
67. Vazlauskaite I, Oswianska A, England P, Khan AG, Cole S, Bankwitz D, et al. Conformational flexibility in the immunoglobulin-like domain of the hepatitis C virus glycoprotein E2. *MBio* (2017) 8(3):e00382-17. doi:10.1128/mBio.00382-17
68. Boisvert M, Zhang W, Elrod EJ, Bernard NF, Villeneuve JP, Bruneau J, et al. Novel E2 glycoprotein tetramer detects hepatitis C virus-specific memory B cells. *J Immunol* (2016) 197:4848–58. doi:10.4049/jimmunol.1600763
69. Folgori A, Capone S, Ruggeri L, Meola A, Sperone E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. *Nat Med* (2006) 12:190–7. doi:10.1038/nm1353
70. Barnes E, Folgori A, Capone S, Swadling L, Ashton S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. *Sci Transl Med* (2012) 4:115ra111. doi:10.1126/scitranslmed.3001355
71. Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M, et al. Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. *Eur J Immunol* (2015) 45:309–16. doi:10.1002/eji.201444686
72. Choo QL, Kuo G, Balston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. *Proc Natl Acad Sci USA* (1994) 91:1294–8. doi:10.1073/pnas.91.4.1294
73. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, et al. Cross-neutralization of epitopes. *J Infect Dis* (2011) 204:1186–90. doi:10.1093/infdis/jir511
74. Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. *J Infect Dis* (2010) 202:862–6. doi:10.1086/655902
75. Wong IA, Bhat R, Hockman D, Logan M, Chen C, Levin A, et al. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. *J Virol* (2014) 88:14278–88. doi:10.1128/JVI.01911-14
76. Fruh K, Picker L. CD8+ T cell programming by cytomegalovirus vectors; applications in prophylactic and therapeutic vaccination. *Curr Opin Immunol* (2017) 47:52–6. doi:10.1016/j.coi.2017.06.010
77. Capone S, Naddeo M, D’Alise AM, Abbate A, Grazioli F, Del Gaudio A, et al. Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. *Mol Ther* (2014) 22:1039–47. doi:10.1038/mt.2014.15
78. Martinello M, Grebely J, Petoumenos K, Gadi SV, et al. hepC reinfection incidence among individuals treated for recent infection. *J Viral Hepat* (2017) 24:359–70. doi:10.1111/jvh.12666
79. Werner JM, Adenuga A, Prottzer U. Immune reconstitution after HCV reinfection incidence among individuals treated for recent infection. *J Viral Hepat* (2017) 24:359–70. doi:10.1111/jvh.12666
80. Knapp S, Warshaw U, Hegazy D, Brackenbury L, Guha IN, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group I human leukocyte antigen-C following exposure to hepatitis C virus. *Hepatology* (2010) 51:1168–75. doi:10.1002/hep.23477
81. Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. *J Hepatol* (2014) 61:538–43. doi:10.1016/j.jhep.2014.05.043
82. Wieland D, Kemming J, Schuch A, Emmerich F, Knolle P, Neumann-Haefelin C, et al. TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. *Nat Commun* (2017) 8:15050. doi:10.1038/ncomms15050
83. Callendret B, Eccleston HB, Hall S, Satterfield W, Capone S, Folgori A, et al. T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. *Hepatology* (2014) 60:1531–40. doi:10.1002/hep.27278
84. Callendret B, Eccleston HB, Satterfield W, Capone S, Folgori A, Cortese R, et al. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral. *Hepatology* (2016) 63:1442–54. doi:10.1002/hep.28309
85. Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, et al. Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection. *Vaccines* (2016) 4(3):27. doi:10.3390/vaccines4030027
86. Walker CM. Designing an HCV vaccine: a unique convergence of prevention and therapy? *Curr Opin Virol* (2017) 23:113–9. doi:10.1016/j.coviro.2017.03.014
87. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology* (2014) 59:318–27. doi:10.1002/hep.26744
88. Institute of Medicine (US) and National Research Council (US). Committee on the Use of Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity. Washington, DC: National Academies Press (2011).
89. Billebeck E, De Jong Y, Dorner M, De La Fuente C, Ploss A. Animal models for hepatitis C. *Curr Top Microbiol Immunol* (2013) 369:49–86. doi:10.1007/978-3-642-73480-7_3
90. Billebeck E, Wollsiberg F, Fahnoe U, Xiao JW, Quirk C, Luna JM, et al. Mouse models of acute and chronic hepatitis virus infection. *Science* (2017) 357:204–8. doi:10.1126/science.aal1962
91. Klennerman P, Barnes EJ. Immunology taught by rats. *Science* (2017) 357:129–30. doi:10.1126/science.aao1084
92. Trivedi S, Murthy S, Sharma H, Hartlage AS, Kumar A, Gadi SV, et al. Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model. *Hepatology* (2018). doi:10.1002/hep.29494
93. Maher L, White B, Hellard M, Addens P, Prins M, Kerr T, et al. Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. *Vaccine* (2010) 28:7273–8. doi:10.1016/j.vaccine.2010.08.085
94. Grebely J, Morris MD, Rice TM, Bruneau J, Cox AL, Kim AX, et al. Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) Study. *Int J Epidemiol* (2013) 42:1649–59. doi:10.1093/ije/dys167
95. Ramlung T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, et al. Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with chimpanzee adenovirus 63 and modified vaccinia ankara vectored vaccines expressing ME-TRAP. *J Infect Dis* (2016) 214:772–81. doi:10.1093/infdis/jiw244
96. Bartschläger R, Baumert TE, Bukh J, Houghton M, Lemon SM, Lindenhack BD, et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies. *Virus Res* (2018) 248:53–62. doi:10.1016/j.virusres.2018.02.016

**Conflict of Interest Statement:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.